ArticleTherapeutic advances in neurological disorders2022

Multiple Sclerosis immunotherapies and COVID-19 mortality: an analysis of the FDA Adverse Event Reporting System.

Maximilian Pistor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.